DB18777InvestigationalProtein Based Therapies
Sacituzumab tirumotecan is a recombinant humanized IgG1 anti-TROP2 monoclonal antibody conjugated to a topoisomerase I inhibitor.
- Mechanism
- Curator reviewed
Pharmacologically active on DNA topoisomerase 1 and Tumor-associated calcium signal transducer 2
- Also known as
- sac-TMT · sacTMT
- Code names
- MK- 2870 · SKB-264
Resolves to
Compound
Targets
What you can answer from here — as of September 12, 2026
Which drugs share a target with Sacituzumab tirumotecan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account